ClinicalTrials.Veeva

Menu
Progressive Medical Research | Port Orange, FL logo

Progressive Medical Research | Port Orange, FL

Research site

Site insights

Top conditions

Top treatments

Donanemab
LY3002813
Obicetrapib
Retatrutide
MK-0616
Crenezumab
LY3372993
Lorundrostat
K-877
Buprenorphine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Bhanu Visvalingam

Verified by this site

Active trials

38 of 157 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Begins enrollment in 2 months
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Tirzepatide
Drug: Placebo

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Active, not recruiting
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disea...

Enrolling
Alzheimer Disease
Drug: Xanomeline Enteric Capsule
Drug: Xanomeline/Trospium Chloride Capsule

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to p...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Glycopyrrolate 21.25 mcg
Drug: Ensifentrine 3 mg

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Active, not recruiting
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic ste...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: Efimosfermin

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388...

Active, not recruiting
Overweight
Obesity
Drug: CT-388
Drug: Placebo

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Dexamethasone
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from base...

Active, not recruiting
Alzheimer's Disease
Drug: E2814
Drug: Lecanemab
Locations recently updated

The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with pl...

Enrolling
Parkinson Disease
Drug: Placebo
Drug: LY4006896

The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people w...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: Mevidalen

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Active, not recruiting
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Drug: Lecanemab

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Trial sponsors

Lilly logo
Pfizer logo
Roche logo
AbbVie logo
Ionis Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
N
Arrowhead Pharmaceuticals logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems